These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 3910219

  • 1. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
    Harrap KR.
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
    [Abstract] [Full Text] [Related]

  • 2. Preclinical antitumor and toxicologic profile of carboplatin.
    Rose WC, Schurig JE.
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():1-19. PubMed ID: 3910215
    [Abstract] [Full Text] [Related]

  • 3. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C.
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [Abstract] [Full Text] [Related]

  • 4. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
    Bregman CL, Williams PD.
    Cancer Chemother Pharmacol; 1986 Apr; 18(2):117-23. PubMed ID: 3539384
    [Abstract] [Full Text] [Related]

  • 5. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
    van Rongen E, Kal HB, Kuijpers WC, van Berkel AH.
    Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
    [Abstract] [Full Text] [Related]

  • 6. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
    Presnov MA, Konovalova AL.
    Arch Geschwulstforsch; 1988 May; 58(1):43-9. PubMed ID: 3285804
    [Abstract] [Full Text] [Related]

  • 7. Effect of oxoplatinum and CBDCA on renal functions in rats.
    Láznícková A, Semecký V, Láznícek M, Zubr V, Koksál J, Kvĕtina J.
    Neoplasma; 1989 May; 36(2):161-9. PubMed ID: 2654665
    [Abstract] [Full Text] [Related]

  • 8. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
    Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F.
    Cancer Chemother Pharmacol; 1988 May; 21(1):40-4. PubMed ID: 3277733
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR.
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1992 Apr; 12(1):49-58. PubMed ID: 1567181
    [Abstract] [Full Text] [Related]

  • 11. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
    Steerenberg PA, Vendrik CP, de Jong WH, de Groot G, Fichtinger-Schepman AM, Scheefhals AP, Schornagel JH.
    Cancer Chemother Pharmacol; 1988 Apr; 22(1):51-7. PubMed ID: 3293840
    [Abstract] [Full Text] [Related]

  • 12. Preclinical toxicology of platinum analogues in dogs.
    Lelieveld P, van der Vijgh WJ, van Velzen D.
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482
    [Abstract] [Full Text] [Related]

  • 13. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
    Lelieveld P, Van der Vijgh WJ, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A.
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
    [Abstract] [Full Text] [Related]

  • 14. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
    Prajda N, Kralovánszky J, Gal F, Kiss F, Kerpel-Fronius S.
    In Vivo; 1989 Mar; 3(4):267-70. PubMed ID: 2519864
    [Abstract] [Full Text] [Related]

  • 16. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR.
    Cancer Chemother Pharmacol; 1982 Mar; 9(3):140-7. PubMed ID: 6761010
    [Abstract] [Full Text] [Related]

  • 17. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, Sheridan C.
    Laryngoscope; 1986 Sep; 96(9 Pt 1):959-74. PubMed ID: 3528727
    [Abstract] [Full Text] [Related]

  • 18. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
    Kimura S, Nakajima Y, Hasegawa S, Tazaki H.
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
    [Abstract] [Full Text] [Related]

  • 19. The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin.
    Dible SE, Siddik ZH, Boxall FE, Harrap KR.
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):813-8. PubMed ID: 2820745
    [Abstract] [Full Text] [Related]

  • 20. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
    Ariyoshi Y, Ota K.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.